Is angiogenesis still an attractive target in metastatic castration‐resistant prostate cancer?

Publisher： John Wiley & Sons Inc

E-ISSN： 1464-410x|116|4|500-501

ISSN： 1464-4096

Source： BJU INTERNATIONAL, Vol.116, Iss.4, 2015-10, pp. : 500-501

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Is prostate cancer changing?: Evolving patterns of metastatic castration‐resistant prostate cancer

By  

CANCER, Vol. 120, Iss. 6, 2014-03 ,pp. : 833-839

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cabazitaxel for the therapy of metastatic castration‐resistant prostate cancer in the aftermath of the CHAARTED trial

By  

BJU INTERNATIONAL, Vol. 116, Iss. 6, 2015-12 ,pp. : 839-840

John Wiley & Sons Inc

Access to resources Recommend Favorite

Optimal sequencing of docetaxel and abiraterone in men with metastatic castration‐resistant prostate cancer

By  

THE PROSTATE, Vol. 270-4137, Iss. 15, 2015-11 ,pp. : 1814-1820

John Wiley & Sons Inc

Access to resources Recommend Favorite

Optimal sequencing of docetaxel and abiraterone in men with metastatic castration‐resistant prostate cancer

By  

THE PROSTATE, Vol. 75, Iss. 15, 2015-11 ,pp. : 1814-1820

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety and efficacy of 2‐weekly cabazitaxel in metastatic castration‐resistant prostate cancer

By  

BJU INTERNATIONAL, Vol. 121, Iss. 2, 2018-02 ,pp. : 203-208

John Wiley & Sons Inc

Access to resources Recommend Favorite